CD33 and acute myeloid leukemia: Studies further demonstrate that 4‐1BB‐engineered autologous DCs enhance the efficacy of anti‐CD33 CAR‐T cells in AML by secreting cytokines and facilitating CAR‐T‐cell recruitment to the bone marrow niche.80